The WasteWatcher
The WasteWatcherProtecting Intellectual Property in an AI World
Intellectual property rights should be protected when artificial intelligence is used in creative works.
The WasteWatcherUSPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The WasteWatcherThe IRA Has Undermined Medicare Part D
The Inflation Reduction Act creates instability in the Medicare Part D Program.
The WasteWatcherNot-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
The WasteWatcherCourt Further Delays Net Neutrality Implementation
On August 1, 2024, the U.S. Court of Appeals for the Sixth Circuit extended the stay on the FCC's latest net neutrality order.
The WasteWatcherFifth Circuit Determines the USF Fee Is a Tax
The Fifth Circuit Court rocked the telecommunications world when it released its ruling on funding the USF.
The WasteWatcherNew Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee's recent hearing on the role of pharmacy benefit managers.
The WasteWatcherAntitrust Regulators Play Monopoly: Rolling the Dice on Artificial Intelligence
Antitrust investigations of AI companies will likely stifle innovation and jeopardize US global competitiveness.
The WasteWatcherBroadband Rollout Requires Municipal Permitting Reform
Municipal leaders can expand broadband connectivity by lifting restraints on cell towers, fiber, and utility pole attachments.
The WasteWatcherDOJ Sets its Antitrust Eyes on Live Nation - Ticketmaster
DOJ’s suit will likely fail to promote competition or bring down prices for consumers in the long run.
The WasteWatcherUSPS Plan Cannot Be Delivered As PMG DeJoy Obstinately Claims
Despite growing evidence of problems, PMG DeJoy doubles down on his Delivering for America plan to supposedly save USPS.
The WasteWatcherThe FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
